Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
What is your approach to isolated thoracic recurrence of NSCLC in an otherwise asymptomatic patient with prior chemoradiation and immunotherapy?
Do you routinely recommend repeat biopsy to confirm recurrence?
Related Questions
Which regimen do you recommend for chemoradiation for a patient with locally advanced, inoperable thymic tumor in the setting of CKD Stage III?
Is dyspnea without radiation pneumonitis a side effect of lung radiation?
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?
What are your top takeaways in Thoracic Cancers from ASCO 2023?
For patients with biphasic mesothelioma who complete pleurectomy/decortication, would you consider offering adjuvant combination immune checkpoint inhibitor therapy vs. platinum chemotherapy?